ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

REDX Redx Pharma Plc

15.00
0.00 (0.00%)
04 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Redx Pharma Plc LSE:REDX London Ordinary Share GB00BSNB6S51 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.00 12.00 17.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Redx Pharma plc Result of Annual General Meeting (9334S)

14/03/2023 11:45am

UK Regulatory


Redx Pharma (LSE:REDX)
Historical Stock Chart


From Dec 2022 to Dec 2024

Click Here for more Redx Pharma Charts.

TIDMREDX

RNS Number : 9334S

Redx Pharma plc

14 March 2023

REDX PHARMA PLC

("Redx" or "the Company")

Result of Annual General Meeting

Alderley Park, UK, 14 March 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease announces that its Annual General Meeting was held at 11am on 14 March 2023, with all resolutions passed by substantial majorities.

The table below sets out the details of the votes put to shareholders

 
 Resolution   Resolution                 Number        % of votes       Number      % of        % of   Total 
   number      name                    of votes             for &     of votes     votes       votes   votes 
                                          for &     discretionary      against   against   withheld*   cast (including 
                                  discretionary                                                        withheld) 
              Receive the 
              Company's 
     1        annual accounts       306,243,523            94.91%   16,434,331     5.09%       0.00%  322,680,605 
             ----------------  ----------------  ----------------  -----------  --------  ----------  ---------------- 
              Re-appoint 
               Ernst & Young 
     2         as auditors          322,677,854           100.00%        2,751     0.00%       0.00%  322,680,605 
             ----------------  ----------------  ----------------  -----------  --------  ----------  ---------------- 
              Re-elect 
               Dr Bernhard 
               Kirschbaum 
     3         as a director        306,241,648            94.91%   16,436,206     5.09%       0.00%  322,680,605 
             ----------------  ----------------  ----------------  -----------  --------  ----------  ---------------- 
              Re-elect 
               Lisa Anson 
     4         as a director        322,678,730           100.00%        1,875     0.00%       0.00%  322,680,605 
             ----------------  ----------------  ----------------  -----------  --------  ----------  ---------------- 
              Re-elect 
               Natalie Berner 
     5         as a director        322,673,730           100.00%        6,875     0.00%       0.00%  322,680,605 
             ----------------  ----------------  ----------------  -----------  --------  ----------  ---------------- 
              Authorise 
               the directors 
               to allot 
     6         shares               322,551,347            99.96%      125,732     0.04%       0.00%  322,680,605 
             ----------------  ----------------  ----------------  -----------  --------  ----------  ---------------- 
              Disapply 
               pre-emption 
     7         rights               322,545,847            99.96%      133,983     0.04%       0.00%  322,680,605 
             ----------------  ----------------  ----------------  -----------  --------  ----------  ---------------- 
 

*A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against'

 
 
   For further information, please 
   contact: 
 
 Redx Pharma Plc                                T: +44 (0)1625 469918 
  UK Headquarters 
  Caitlin Pearson, Head of Communications 
  ir@redxpharma.com 
 
  Lisa Anson, Chief Executive Officer 
 
   US Office 
   Peter Collum, Chief Financial Officer 
 
 SPARK Advisory Partners (Nominated Adviser)     T: +44 (0)203 368 
                                                  3550 
 Matt Davis/ Adam Dawes 
 
 WG Partners LLP (Joint Broker)                  T: +44 (0)203 705 
                                                  9330 
 Claes Spång/ Satheesh Nadarajah/ 
  David Wilson 
 
 Panmure Gordon (UK) Limited (Joint Broker)      T: +44 (0)207 886 
                                                  2500 
 Rupert Dearden/ Freddy Crossley/ Emma 
  Earl 
 
 FTI Consulting                                  T: +44 (0)203 727 
                                                  1000 
 Simon Conway/ Ciara Martin 
 
 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022, with topline data expected in Q1 2024. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report both monotherapy and combination with anti-PD-1 Phase 2 data during 2023. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA/IND application at the end of 2023.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDZGMFMDMGFZM

(END) Dow Jones Newswires

March 14, 2023 07:45 ET (11:45 GMT)

1 Year Redx Pharma Chart

1 Year Redx Pharma Chart

1 Month Redx Pharma Chart

1 Month Redx Pharma Chart

Your Recent History

Delayed Upgrade Clock